In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xenogen Corp.

Division of PerkinElmer Inc.
http://www.xenogen.com/wt/page/index

Latest From Xenogen Corp.

Private Device Companies Step-Up to the Public Market

Encouraged by successes in the biotech space, public market investors' interest in the device arena has returned in 2004 to support 10 companies' IPOs so far. Windhover's analysis of the valuations achieved indicate that private investors in these companies have, on average, enjoyed larger returns than their biotech counterparts.
BioPharmaceutical Business Strategies

Imaging in its Heyday: Research Applications (Part 1)

Biomolecular imaging is upgrading diagnostic imaging's stodgy reputation as scientists increasingly use it to improve both pharmaceutical research and clinical care. Part I of a two-part series explores researchers' excitement about biomolecular imaging's potential to improve the drug development process. Many companies see research applications as a way to prime the marketplace for clinical applications. But venture capitalists think research is a limited opportunity.
Medical Device Business Strategies

Drug Development's Preclinical Bottleneck

Thanks to genomics, combinatorial chemistry, and high-throughput screening, pharmaceutical companies have more drug leads than ever. But which are the drugs? Start-up firms with faster, smarter approaches to preclinical testing may help sort out the answers. Information technology will play a key role in lead optimization as new firms with simulation software are helping drug developers plot development strategies earlier than ever.
BioPharmaceutical Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Transgenics
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • PerkinElmer Inc.
  • Senior Management
  • David Carter, Chmn. & CEO
    Pamela Contag, PhD, Pres.
  • Contact Info
  • Xenogen Corp.
    Phone: (508) 435-9500
    68 Elm Street
    Hopkinton, MA 01748
    USA
UsernamePublicRestriction

Register